The developers of Sputnik V, the Russian vaccine against Covid-19, have urged health regulators to look into a University of Oxford study on the correlation between the occurrence of rare blood clotting and vaccines currently injected on a mass scale globally.
The Oxford University study, based on data from over 35 million people, was published on 15 April. It has highlighted blood clotting risks in US manufactured vaccines based on a mRNA platform, hitherto an untested technology.
Russian developers have pointed to the risk of an individual developing cerebral vein thrombosis, which has resulted in the suspension of the use of vaccines produced by AstraZeneca as well as Johnson & Johnson, since the latter “appears to be very similar for AstraZeneca’s vaccine (5 in a million) as for Pfizer’s and Moderna’s mRNA vaccines (4 in a million).”
Johnson & Johnson’s Covid-19 vaccine has been suspended in the US while such cases are being investigated. Several countries have since delayed the rollout of both the Johnson & Johnson and AstraZeneca vaccines which use an adenoviral vector based platforms.
A hack into the European Medicines Agency (EMA) servers was leaked on the web revealing that Pfizer, an mRNA vaccine manufacturer, faced serious problems during the switch between lab and the mass production of their product. The data breach revealed “that RNA integrity of the full-scale production samples decreased drastically, resulting in a subsequent decrease in safety. Moreover, the low integrity combined with high dosage means that the patient receives more truncated RNA, which does not create Covid-19 immunity and causes additional harmful stress on human immunity instead,” Russian news outlet Sputnik reported.
Meanwhile, the number of thrombosis cases after a Corona vaccination with the vaccine from the pharmaceutical company AstraZeneca continues to rise. The Paul Ehrlich Institute (PEI) stated that by April 14, 55 cases of sinus vein thrombosis (blood clots in a sinus vein in the brain) after an AstraZeneca vaccination had been reported “as part of the spontaneous detection”.
With 55 cases of cerebral vein thrombosis and eleven deaths, one can sum up: Since the resumption of the AstraZeneca vaccinations on March 18, the number of illnesses and deaths has quadrupled. Since the recommendation to only use the vaccine for people over 60, there have been at least 13 more cases and three deaths.
However , the PEI does not see a clear connection between cerebral vein thrombosis and the AstraZeneca vaccine: “The identification of the possible cause of the occurrence of the very rare thrombosis after vaccination with the Covid-19 vaccine from AstraZeneca is a prerequisite for possible future therapy options and has not yet been clarified.”
Nevertheless, the PEI issued a clear warning for people vaccinated with AstraZeneca: “People who have been vaccinated should see a doctor immediately if they develop symptoms such as shortness of breath, chest pain, arm or leg swelling in the weeks after vaccination. Even people who have small punctiform bleeding (petechiae) or bruises on the skin in the days after vaccination develop the vaccination site should see a doctor immediately.”
The main symptom, however, is “severe or persistent headaches (…) which do not respond or respond only inadequately to the usual, over-the-counter analgesics”. In such cases or “if additional neurological symptoms such as hemiplegia and/or sensory disorders, speech disorders or epileptic seizures develop, further diagnostics should be carried out immediately”.
On April 7, the European Medicines Agency (EMA) admitted that a possible link between the vaccine and AstraZeneca cerebral venous thrombosis could exist. These should be included in the list of possible side effects. However, since these would only occur very rarely, the EMA stuck to its unreserved vaccination recommendation.
According to the PEI, 3 992 707 first doses plus 2 919 second doses of the AstraZeneca vaccine had been injected by April 13. For image reasons, the pharmaceutical company AstraZeneca has decided to sell the vaccine under the name “Vaxzevria” in future:
Since the start of the use of the AstraZeneca vaccine in France, 23 cases (including eight deaths) of rare thromboses and coagulation abnormalities have been recorded. And this, out of 2 725 000 injections carried out on April 8 with this vaccine in the country.
According to French health authorities, nine new cases of atypical thrombosis (clots) and two cases of coagulation disorders associated with AstraZeneca’s Covid-19 vaccine, with four additional deaths, occurred in France between the 2nd and the 8th of April.
Since the start of vaccination with this jab, there have been “23 cases, including eight deaths in total”, with rare thromboses and coagulation abnormalities which have occurred in France, according to information released on April 16 by the French Medicines Agency (ANSM).
Among them, “21 cases were associated with cerebral venous thrombosis and/or digestive thrombosis and two cases with isolated disseminated intravascular coagulations (DIC)”, according to the same source.
The nine new cases of rare thrombosis concern people who present “a profile different from that” of the cases declared previously, noted the ANSM because the age of the patients is higher: “They are four women and five men, older (average age 62 years), who presented more digestive thrombosis.”
Due to the rare cases of thrombosis spotted in Europe and France, since March 19, the AstraZeneca vaccine is no longer administered to those under 55 in France. For this category of people who have already received a dose of this vaccine, the High Authority for Health has recommended a second dose with Pfizer or Moderna.